CXCL16 and oxLDL are induced in the onset of diabetic nephropathy
Corresponding Author
Paul Gutwein
pharmazentrum frankfurt/ZAFES, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
Correspondence to: Dr. Paul GUTWEIN, pharmazentrum frankfurt, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany.Tel.: +49 69 6301 4920Fax: +49 69 6301 79 42E-mail: [email protected]Search for more papers by this authorMohamed Sadek Abdel-Bakky
pharmazentrum frankfurt/ZAFES, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
Search for more papers by this authorKai Doberstein
pharmazentrum frankfurt/ZAFES, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
Search for more papers by this authorAnja Schramme
Institute of Reconstructive Neurobiology, Life & Brain Center, University of Bonn and Hertie Foundation, Bonn, Germany
Search for more papers by this authorJanet Beckmann
pharmazentrum frankfurt/ZAFES, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
Search for more papers by this authorLiliana Schaefer
pharmazentrum frankfurt/ZAFES, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
Search for more papers by this authorKerstin Amann
Department of Urology, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany
Search for more papers by this authorAnke Doller
pharmazentrum frankfurt/ZAFES, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
Search for more papers by this authorNicole Kämpfer-Kolb
pharmazentrum frankfurt/ZAFES, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
Search for more papers by this authorAbdel-Aziz H. Abdel-Aziz
Department of Pharmacology and Toxicology, Faculty of Pharmacology, Al-Azhar University, Cairo, Egypt
Search for more papers by this authorEl Sayed M. El Sayed
Department of Pharmacology and Toxicology, Faculty of Pharmacology, Al-Azhar University, Cairo, Egypt
Search for more papers by this authorJosef Pfeilschifter
pharmazentrum frankfurt/ZAFES, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
Search for more papers by this authorCorresponding Author
Paul Gutwein
pharmazentrum frankfurt/ZAFES, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
Correspondence to: Dr. Paul GUTWEIN, pharmazentrum frankfurt, Klinikum der Johann Wolfgang Goethe-Universität Frankfurt, Theodor-Stern-Kai 7, D-60590 Frankfurt am Main, Germany.Tel.: +49 69 6301 4920Fax: +49 69 6301 79 42E-mail: [email protected]Search for more papers by this authorMohamed Sadek Abdel-Bakky
pharmazentrum frankfurt/ZAFES, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
Search for more papers by this authorKai Doberstein
pharmazentrum frankfurt/ZAFES, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
Search for more papers by this authorAnja Schramme
Institute of Reconstructive Neurobiology, Life & Brain Center, University of Bonn and Hertie Foundation, Bonn, Germany
Search for more papers by this authorJanet Beckmann
pharmazentrum frankfurt/ZAFES, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
Search for more papers by this authorLiliana Schaefer
pharmazentrum frankfurt/ZAFES, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
Search for more papers by this authorKerstin Amann
Department of Urology, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, Germany
Search for more papers by this authorAnke Doller
pharmazentrum frankfurt/ZAFES, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
Search for more papers by this authorNicole Kämpfer-Kolb
pharmazentrum frankfurt/ZAFES, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
Search for more papers by this authorAbdel-Aziz H. Abdel-Aziz
Department of Pharmacology and Toxicology, Faculty of Pharmacology, Al-Azhar University, Cairo, Egypt
Search for more papers by this authorEl Sayed M. El Sayed
Department of Pharmacology and Toxicology, Faculty of Pharmacology, Al-Azhar University, Cairo, Egypt
Search for more papers by this authorJosef Pfeilschifter
pharmazentrum frankfurt/ZAFES, University Hospital, Goethe University Frankfurt, Frankfurt, Germany
Search for more papers by this authorAbstract
Diabetic nephropathy (DN) is a major cause of end-stage renal failure worldwide. Oxidative stress has been reported to be a major culprit of the disease and increased oxidized low density lipoprotein (oxLDL) immune complexes were found in patients with DN. In this study we present evidence, that CXCL16 is the main receptor in human podocytes mediating the uptake of oxLDL. In contrast, in primary tubular cells CD36 was mainly involved in the uptake of oxLDL. We further demonstrate that oxLDL down-regulated α3-integrin expression and increased the production of fibronectin in human podocytes. In addition, oxLDL uptake induced the production of reactive oxygen species (ROS) in human podocytes. Inhibition of oxLDL uptake by CXCL16 blocking antibodies abrogated the fibronectin and ROS production and restored α3 integrin expression in human podocytes. Furthermore we present evidence that hyperglycaemic conditions increased CXCL16 and reduced ADAM10 expression in podocytes. Importantly, in streptozotocin-induced diabetic mice an early induction of CXCL16 was accompanied by higher levels of oxLDL. Finally immunofluorescence analysis in biopsies of patients with DN revealed increased glomerular CXCL16 expression, which was paralleled by high levels of oxLDL. In summary, regulation of CXCL16, ADAM10 and oxLDL expression may be an early event in the onset of DN and therefore all three proteins may represent potential new targets for diagnosis and therapeutic intervention in DN.
References
- 1 Gin H, Rigalleau V, Aparicio M. Lipids, protein intake, and diabetic nephropathy. Diabetes Metab. 2000; 26: 45–53.
- 2 Forbes JM, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes. 2008; 57: 1446–54.
- 3 Deslypere JP. Modified lipoproteins in diabetes. J Intern Med Suppl. 1994; 736: 69–74.
- 4 Lyons TJ. Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes? Diabet Med. 1991; 8: 411–9.
- 5 Lee HS. Oxidized LDL, glomerular mesangial cells and collagen. Diabetes Res Clin Pract. 1999; 45: 117–22.
- 6 Nishida Y, Oda H, Yorioka N. Effect of lipoproteins on mesangial cell proliferation. Kidney Int Suppl. 1999; 71: S51–3.
- 7 Wheeler DC, Chana RS, Topley N, et al . Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury. Kidney Int. 1994; 45: 1628–36.
- 8 Claise C, Edeas M, Chaouchi N, et al . Oxidized-LDL induce apoptosis in HUVEC but not in the endothelial cell line EA.hy 926. Atherosclerosis. 1999; 147: 95–104.
- 9 Kamanna VS, Pai R, Ha H, et al . Oxidized low-density lipoprotein stimulates monocyte adhesion to glomerular endothelial cells. Kidney Int. 1999; 55: 2192–202.
- 10 Bussolati B, Deregibus MC, Fonsato V, et al . Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol. 2005; 16: 1936–47.
- 11 Witztum JL, Steinberg D. The oxidative modification hypothesis of atherosclerosis: does it hold for humans? Trends Cardiovasc Med. 2001; 11: 93–102.
- 12 Akiba S, Chiba M, Mukaida Y, et al . Involvement of reactive oxygen species and SP-1 in fibronectin production by oxidized LDL. Biochem Biophys Res Commun. 2003; 310: 491–7.
- 13 Brune B, Zhou J, von Knethen A. Nitric oxide, oxidative stress, and apoptosis. Kidney Int Suppl. 2003; S22–4.
- 14 Chade AR, Mushin OP, Zhu X, et al . Pathways of renal fibrosis and modulation of matrix turnover in experimental hypercholesterolemia. Hypertension. 2005; 46: 772–9.
- 15 Reddy S, Santanam N, Reddy PP, et al . Interaction of Interceed oxidized regenerated cellulose with macrophages: a potential mechanism by which Interceed may prevent adhesions. Am J Obstet Gynecol. 1997; 177: 1315–20.
- 16 Ding G, van Goor H, Ricardo SD, et al . Oxidized LDL stimulates the expression of TGF-beta and fibronectin in human glomerular epithelial cells. Kidney Int. 1997; 51: 147–54.
- 17 Gruden G, Perin PC, Camussi G. Insight on the pathogenesis of diabetic nephropathy from the study of podocyte and mesangial cell biology. Curr Diabetes Rev. 2005; 1: 27–40.
- 18 Kanwar YS, Wada J, Sun L, et al . Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med. 2008; 233: 4–11.
- 19 Dalla VM, Masiero A, Roiter AM, et al . Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes. 2003; 52: 1031–5.
- 20 Pagtalunan ME, Miller PL, Jumping-Eagle S, et al . Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest. 1997; 99: 342–8.
- 21 Steffes MW, Schmidt D, McCrery R, et al . Glomerular cell number in normal subjects and in type 1 diabetic patients. Kidney Int. 2001; 59: 2104–13.
- 22 White KE, Bilous RW, Marshall SM, et al . Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes. 2002; 51: 3083–9.
- 23 Kita T, Kume N, Minami M, et al . Role of oxidized LDL in atherosclerosis. Ann N Y Acad Sci. 2001; 947: 199–205.
- 24 Zingg JM, Ricciarelli R, Azzi A. Scavenger receptors and modified lipoproteins: fatal attractions? IUBMB Life. 2000; 49: 397–403.
- 25 Shimaoka T, Kume N, Minami M, et al . Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem. 2000; 275: 40663–6.
- 26 Shimaoka T, Nakayama T, Fukumoto N, et al . Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J Leukoc Biol. 2004; 75: 267–74.
- 27 Abel S, Hundhausen C, Mentlein R, et al . The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol. 2004; 172: 6362–72.
- 28 Gough PJ, Garton KJ, Wille PT, et al . A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. J Immunol. 2004; 172: 3678–85.
- 29 Geissmann F, Cameron TO, Sidobre S, et al . Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids. PLoS Biol. 2005; 3: e113.
- 30 Matloubian M, David A, Engel S, et al . A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nat Immunol. 2000; 1: 298–304.
- 31 Okamura DM, Lopez-Guisa JM, Koelsch K, et al . Atherogenic scavenger receptor modulation in the tubulointerstitium in response to chronic renal injury. Am J Physiol Renal Physiol. 2007; 293: F575–85.
- 32 Saleem MA, O’Hare MJ, Reiser J, et al . A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol. 2002; 13: 630–8.
- 33 Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001; 25: 402–8.
- 34 Schaefer L, Tsalastra W, Babelova A, et al . Decorin-mediated regulation of fibrillin-1 in the kidney involves the insulin-like growth factor-I receptor and mammalian target of rapamycin. Am J Pathol. 2007; 170: 301–15.
- 35 Susztak K, Ciccone E, McCue P, et al . Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med. 2005; 2: e45.
- 36 Schramme A, Abdel-Bakky MS, Gutwein P, et al . Characterization of CXCL16 and ADAM10 in the normal and transplanted kidney. Kidney Int. 2008; 74: 328–38.
- 37 Li C, Ruotsalainen V, Tryggvason K, et al . CD2AP is expressed with nephrin in developing podocytes and is found widely in mature kidney and elsewhere. Am J Physiol Renal Physiol. 2000; 279: F785–92.
- 38 Liu G, Kaw B, Kurfis J, et al . Neph1 and nephrin interaction in the slit diaphragm is an important determinant of glomerular permeability. J Clin Invest. 2003; 112: 209–21.
- 39 Kretzler M. Regulation of adhesive interaction between podocytes and glomerular basement membrane. Microsc Res Tech. 2002; 57: 247–53.
- 40 Li JJ, Kwak SJ, Jung DS, et al . Podocyte biology in diabetic nephropathy. Kidney Int Suppl. 2007; S36–S42.
- 41 Ha H, Hwang IA, Park JH, et al . Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract. 2008; 13: S42–5.
- 42 Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes. 1991; 40: 405–12.
- 43 Kelly DJ, Aaltonen P, Cox AJ, et al . Expression of the slit-diaphragm protein, nephrin, in experimental diabetic nephropathy: differing effects of anti-proteinuric therapies. Nephrol Dial Transplant. 2002; 17: 1327–32.
- 44 Mifsud SA, Allen TJ, Bertram JF, et al . Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia. 2001; 44: 878–82.
- 45 Dronavalli S, Duka I, Bakris GL. The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab. 2008; 4: 444–52.
- 46 Gurley SB, Coffman TM. The renin-angiotensin system and diabetic nephropathy. Semin Nephrol. 2007; 27: 144–52.
- 47 Susztak K, Raff AC, Schiffer M, et al . Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes. 2006; 55: 225–33.
- 48 Hofnagel O, Luechtenborg B, Weissen-Plenz G, et al . Statins and foam cell formation: impact on LDL oxidation and uptake of oxidized lipoproteins via scavenger receptors. Biochim Biophys Acta. 2007; 1771: 1117–24.
- 49 Regoli M, Bendayan M. Alterations in the expression of the alpha 3 beta 1 integrin in certain membrane domains of the glomerular epithelial cells (podocytes) in diabetes mellitus. Diabetologia. 1997; 40: 15–22.
- 50 White JM. ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol. 2003; 15: 598–606.
- 51 Millichip MI, Dallas DJ, Wu E, et al . The metallo-disintegrin ADAM10 (MADM) from bovine kidney has type IV collagenase activity in vitro. Biochem Biophys Res Commun. 1998; 245: 594–8.
- 52 Zheng S, Carlson EC, Yang L, et al . Podocyte-specific overexpression of the antioxidant metallothionein reduces diabetic nephropathy. J Am Soc Nephrol. 2008; 19: 2077–85.
- 53 Kim NH, Rincon-Choles H, Bhandari B, et al . Redox dependence of glomerular epithelial cell hypertrophy in response to glucose. Am J Physiol Renal Physiol. 2006; 290: F741–51.
- 54 Atchley DH, Lopes-Virella MF, Zheng D, et al . Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy. Diabetologia. 2002; 45: 1562–71.
- 55 Coritsidis G, Rifici V, Gupta S, et al . Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro. Kidney Int. 1991; 39: 858–66.
- 56 Bosmans JL, Holvoet P, Dauwe SE, et al . Oxidative modification of low-density lipoproteins and the outcome of renal allografts at 1 1/2 years. Kidney Int. 2001; 59: 2346–56.
- 57 Ujihara N, Sakka Y, Takeda M, et al . Association between plasma oxidized low-density lipoprotein and diabetic nephropathy. Diabetes Res Clin Pract. 2002; 58: 109–14.